Safety and Tolerability Study of ST-503 for Small Fiber Neuropathy-associated Refractory Pain

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions
Chronic Neuropathic Pain
Interventions
GENETIC

ST-503

Genomic Medicine

PROCEDURE

Sham (No Treatment)

Sham Procedure

Trial Locations (10)

10027

NOT_YET_RECRUITING

Columbia University, New York

21218

NOT_YET_RECRUITING

Johns Hopkins University, Baltimore

23284

NOT_YET_RECRUITING

Virginia Commonwealth University, Richmond

27514

NOT_YET_RECRUITING

University of North Carolina Medical Center, Chapel Hill

37235

NOT_YET_RECRUITING

Vanderbilt University, Nashville

72205

NOT_YET_RECRUITING

University of Arkansas for Medical Sciences, Little Rock

84112

NOT_YET_RECRUITING

University of Utah, Salt Lake City

85260

NOT_YET_RECRUITING

HonorHealth, Scottsdale

02114

RECRUITING

Massachusetts General Hospital, Boston

03766

NOT_YET_RECRUITING

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
lead

Sangamo Therapeutics

INDUSTRY